Patient Group to House Democrats: Don’t Cut Bad Deal with Big Pharma

June 11, 2018 Press Releases

WASHINGTON, D.C. — “Don’t Get Fooled Again.” That’s the message from cancer patient and founder and president of Patients For Affordable Drugs David Mitchell to 50 Democratic members of the House. The members all signed on to a letter supporting drug corporations’ lobbying efforts to rollback Big Pharma’s contribution to Medicare that saves patients and taxpayers money.

ICYMI: A Push for Affordable Prices for Taxpayer-Funded Drugs

May 29, 2018 News

“We have an incredibly powerful, incredibly productive research and development program being run by N.I.H.,” Ameet Sarpatwari, an instructor at Harvard Medical School, said. “Taxpayers put in money that is paying big dividends, and yet we pay higher prices for prescription drugs than any other country. In effect, we have taxpayers paying twice.”

Patients For Affordable Drugs Joins Cystic Fibrosis Patients to Demand That Vertex Lower Its Drug Prices

May 17, 2018 Press Releases

St. Louis — Patients For Affordable Drugs stood with Lora Moser, a cystic fibrosis patient unable to afford the medicines her family spent decades fundraising to develop, and launched a new campaign demanding that Vertex Pharmaceuticals lower the price of its life-extending drugs.

Moser and Patients For Affordable Drugs were represented Thursday at a meeting of the Institute For Clinical and Economic Review (ICER) by Juliana Keeping, mother to Eli, 5, who also has cystic fibrosis.

The problem is the price: 5 reasons the cystic fibrosis community and its allies must band together to speak out about our drug prices – right now.

May 17, 2018 Blogs

But I live in fear that we won’t be able to afford his medication from Vertex. I live in fear that stock buybacks and CEO pay raises will come before lowering the price of Eli’s drugs. That’s why I decided to fight back. That’s why I’m calling on all shareholders and the cystic fibrosis community to demand Vertex use its windfall in corporate tax breaks to lower the price of Cystic Fibrosis drugs.

Patients For Affordable Drugs Delivers Petition to AbbVie Calling for End to Biosimilar Delay Deals

May 15, 2018 Press Releases

WASHINGTON, DC — Patients For Affordable Drugs sent a petition with more than 1,000 signatures demanding pharmaceutical giant AbbVie stop delaying the introduction of biosimilar alternatives to Humira, a move that hurts patients by keeping prices high.

The company announced in April it had inked a deal with manufacturer Samsung Bioepis that would guarantee AbbVie market exclusivity on Humira — the world’s top-selling drug — through 2023. It’s the second deal the drugmaker has signed in the last year to stifle competition and maintain high prices in the US.

Our Stories

Elected officials and policymakers need to hear our stories. We need your help to share them. More stories

JOIN US

Patients For Affordable Drugs is the only independent national patient organization focused exclusively on achieving policy changes to lower the price of prescription drugs.